BioWorld

Sep. 29, 2003

View Archived Issues

Novogen Cancer Subsidiary Files IPO, Seeks Up To $13M

Chromosome 15's 4 Mutant Genes Focus Hotspots For Derangements In Michigan, Penn Research Centers

Hollis-Eden Raises $62.5M; This Time In Public Offering

Angiotech Garners $218.8M With Follow-On Public Stock Offering

Appointments And Advancements

Other News To Note

After Phase II Miss, HGS Stops Repifermin Venous Ulcers Work

Human Genome Sciences Inc. said it would terminate development of repifermin in chronic venous ulcers following a disappointing Phase II trial. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Feb. 4, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...